Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Randomized Placebo-controlled Trial
100%
Male Patients
100%
Supraspinal
100%
Tetrahydrocannabinol
100%
Chronic Neuropathic Pain
100%
Conditioned Pain Modulation
100%
Placebo
25%
Interaction Effect
25%
Chronic Pain
25%
Modulation Response
25%
LF-HF Ratio
25%
Treatment Options
12%
Brain Regions
12%
Randomized Double-blind
12%
Placebo-controlled
12%
Multiple Domains
12%
Dysregulation
12%
Parasympathetic Tone
12%
Clinical Trial Registry
12%
Autonomic Nervous System
12%
Heart Rate Variability
12%
High-order
12%
Dorsolateral Prefrontal Cortex (DLPFC)
12%
Functional Connectivity
12%
Pain Mechanisms
12%
Neuropathic Pain
12%
Vagal Tone
12%
Radicular
12%
Connectivity Change
12%
Emerging Treatments
12%
Rostral Ventrolateral Medulla
12%
Low-high Frequency
12%
Top-down Effects
12%
Sublingual Administration
12%
Variability Ratio
12%
T-10
12%
Central Pain Modulation
12%
Resting-state Functional Magnetic Resonance Imaging
12%
Single Administration
12%
Autonomic Nervous System Regulation
12%
Patients with Chronic Pain
12%
Autonomic Balance
12%
Medicine and Dentistry
Placebo
100%
Neuropathic Pain
100%
Tetrahydrocannabinol
100%
Dronabinol
100%
Pain Modulation
100%
Parasympathetic Tone
100%
Oral
100%
Chronic Pain
42%
Autonomic Nervous System
28%
Clinical Trial
14%
Heart Rate Variability
14%
Single Drug Dose
14%
Brain Region
14%
Functional Magnetic Resonance Imaging
14%
Functional Connectivity
14%
Emerging Treatment
14%
Dorsolateral Prefrontal Cortex
14%
Rostral Ventrolateral Medulla
14%
Sublingual Administration
14%
Treatment Option
14%
Neuroscience
Parasympathetic Tone
100%
Placebo
100%
Neuropathic Pain
100%
Tetrahydrocannabinol
100%
Autonomic Nervous System
25%
Functional Magnetic Resonance Imaging
12%
Heart Rate Variability
12%
Functional Connectivity
12%
Dorsolateral Prefrontal Cortex
12%
Medulla
12%
Brain Region
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Neuropathic Pain
100%
Tetrahydrocannabinol
100%
Dronabinol
100%
Chronic Pain
42%
Clinical Trial
14%
Sublingual Administration
14%